Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 22Observational 2Expanded_access 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Carcinoma, Non-Small-Cell Lung 32Multiple Myeloma 26Neoplasms 25Recurrence 23Melanoma 19Leukemia, Myeloid, Acute 16Breast Neoplasms 15Prostatic Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Ovarian Neoplasms 8Lymphoma 8Glioma 8Colorectal Neoplasms 8Small Cell Lung Carcinoma 7Lymphoma, Large B-Cell, Diffuse 7Carcinoma, Renal Cell 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Cholangiocarcinoma 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Neoplasm Metastasis 5Leukemia, Lymphocytic, Chronic, B-Cell 5Thyroid Neoplasms 4Lymphoma, Mantle-Cell 4

Interventions

nilotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Blast Crisis × Clear all
NCT00905593 2012-07-18

ENACT

Novartis

Approved for marketing
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00413270 2011-07-13

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Novartis

No longer available
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡